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Intractable seizures are just one manifestation of ‘refractory epilepsy’, which can be recognized as a distinct condition with
multifaceted dimensions, including neurobiochemical plastic changes, cognitive decline and psychosocial dysfunction, leading
to dependent behaviour and a restricted lifestyle. The biological basis of ‘refractoriness’ is likely to be multifactorial, and may
include the severity of the syndrome and/or underlying neuropathology, abnormal reorganization of neuronal circuitry, alteration
in neurotransmitter receptors, ion channelopathies, reactive autoimmunity, and impaired antiepileptic drug (AED) penetration
to the seizure focus. Some of these deleterious changes may be a consequence of recurrent seizures. We hypothesize that
‘refractory epilepsy’ may be prevented by interrupting this self-perpetuating progression. There is increasing evidence that
these patients can be identified early in the clinical course and, thus, be targeted early for effective therapeutic intervention.
Failure of two first-line AEDs due to lack of efficacy or poor tolerability should prompt consideration of epilepsy surgery in a
patient with a resectable brain abnormality. For the majority not suitable for ‘curative’ surgery, AEDs should be combined with
the aim of achieving ‘synergism’. This strategy has the potential to improve outcome by preventing the insidious progression to
intractable ‘refractoriness’ and a downward spiralling quality of life.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Epilepsy affects 4–10 per 1000 people1, which
translates into approximately 50 million sufferers
worldwide2. The prevalence is set to rise with
the ageing of the population3. Despite antiepileptic
drug (AED) treatment, up to one-third of patients con-
tinue to have seizures4, 5. Many will have ‘refractory
epilepsy’. We wish to propose a hypothesis for the
conceptual understanding and prevention of refractory
epilepsy based on accumulated laboratory findings,
and an improved knowledge of the ‘natural history’ of
treated epilepsy5.
REFRACTORY EPILEPSY AS A DISTINCT
CONDITION
Although criteria for defining ‘refractory epilepsy’ are
elusive e.g. number of drugs tried, dose of drugs,
duration of treatment etc.6, 7, a hard core of 20–30%
of patients continue to have seizures that appear to
be resistant to all pharmacological manipulations8.
These patients are usually treated with multiple
AEDs, which, in combination, may produce sedative
and behavioural toxicity9, 10. High seizure frequency,
prolonged seizures and episodes of status epilepticus
can lead to cognitive decline11. A long period of
imperfect seizure control produces disturbed psy-
chosocial functioning resulting, for instance, in poor
academic achievement, diminished self-esteem, low
rates of marriage, dependent behaviour, and restricted
lifestyle, all leading to unsatisfactory quality of
life12, 13. In addition, refractory epilepsy is associated
with excess mortality, particularly due to sudden unex-
pected death14. ‘Refractory epilepsy’, therefore, may
be better understood as a distinct condition comprising
of a constellation of disabilities with recurrent seizures
being just one of its manifestations (Table 1).
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Table 1: Dimensions of refractory epilepsy.
Intractable seizures
Excessive drug burden
Neurobiochemical plastic changes
Cognitive decline
Psychosocial dysfunction
Dependent behaviour
Restricted lifestyle
Unsatisfactory quality of life
Increased mortality
REFRACTORY EPILEPSY AS A
MULTIFACTORIAL CONDITION
With the identification of the genetic defects in several
idiopathic epilepsy syndromes, important insights
into the mechanisms underlying the pathogenesis
of epilepsy are emerging15. However, what causes
epilepsy to become ‘refractory’ has not been well
studied. The biological basis of ‘refractoriness’ is
likely to be multifactorial and variable. Some possible
contributing factors are listed in Table 2.
Table 2: Putative factors contributing to the biological basis of
refractory epilepsy.
Syndromic classification e.g. childhood epileptic encephalopathies
Causative neuropathology e.g. mesial temporal sclerosis, cortical
dysplasia
Hyperexcitable and disinhibited neuronal network reorganization
e.g. mossy fibre sprouting
Altered neurotransmitter receptors e.g. composition/functioning of
GABA/glutamate receptors
Ion channelopathies e.g. sodium, calcium, potassium channels
Reactive autoimmunity e.g. autoantibodies against glutamic acid
decarboxylase
Impaired antiepileptic drug penetration e.g. P-glycoprotein
expression at blood–brain barrier
GABA = γ -aminobutyric acid.
Syndromic classification
Among the idiopathic (genetic) epilepsies, prognosis
is often determined by the behaviour of the underlying
syndrome16. Some (e.g. Rolandic epilepsy) appear
to be ‘benign’ and may be outgrown by the child.
Others (e.g. juvenile myoclonic epilepsy) respond
well to AEDs, but are prone to relapse when drugs
are withdrawn17. A few, such as the devastating
encephalopathic disorders of infancy, have no consis-
tently effective treatment18.
Gross pathology
Similar heterogeneity in outcome is beginning to
be recognized in the symptomatic epilepsies. Out-
come studies have provided evidence that certain
structural abnormalities, particularly hippocampal
sclerosis (HS) and cortical dysplasia (CD), are
more likely to produce pharmacoresistant epilepsy
than other pathologies19. This again suggests that
response to AED treatment is influenced by the
causative neuropathology20. In our prospective study
of 550 patients with localization-related epilepsy,
HS and CD were also associated with the worst
prognosis21. However, marked variability in response
to treatment was observed within any given aetiolog-
ical group, so that some patients remained seizure-
free after withdrawal from AED therapy whereas
others continued to have seizures despite taking
polypharmacy with up to four AEDs. This implies that
outcome is affected by factors other than the gross
pathology.
Neuronal circuitry and neurotransmitter
receptors
These factors may include abnormalities in neuronal
circuitry and neurotransmitter receptors. Such changes
have been most extensively studied in HS, where
there is selective neuronal loss in the CA1 and
CA4 regions of the hippocampus with gliosis and
‘sprouting’ of mossy fibres, which may lead to a
hyperexcitable state22, 23. Reorganization of mossy
fibre synapses can also be observed in cases other than
HS, such as in some models of generalized motor and
absence seizures24. Changes in γ -aminobutyric acid
(GABA, inhibitory) and glutamate (excitatory) neu-
rotransmitter receptors, in terms of their composition,
sensitivity and distribution, have been reported in the
epileptic hippocampus25, 26. However, the direction of
the changes is not consistent and how they may alter
drug response has not been clearly defined27.
Ion channelopathies
An increasing number of channelopathies, including
mutations in ligand-gated and voltage-gated ion
channels, are being identified in human genetic
epilepsies28–32. It has been shown in vitro that the
mutated nicotinic receptors responsible for some cases
of autosomal dominant nocturnal frontal epilepsy are
more responsive to carbamazepine than their wild-type
counterparts33. Mutations in ion channels, therefore,
may play a role in the genesis of refractory epilepsy
by altering response to AEDs.
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Autoimmunity
There has been renewed interest in the potential role
of autoimmunity in the manifestation and control
of epilepsy34. Circulating antibodies to the GluR3
subunit of the glutamate receptor have been found
in some patients with Rasmussen’s encephalitis, a
condition associated with intractable seizures often
requiring radical surgery35. AntiGM1 antibodies,
a proconvulsant in animal models, have been re-
ported in a few patients with refractory partial-
onset seizures36. More recently, autoantibodies to
glutamic acid decarboxylase, which catalyses the
conversion of glutamate to GABA, have been detected
in patients with drug-resistant epilepsy37–39. Although
these autoantibodies all have ‘theoretical’ relevance
to the epileptogenic process, their relationship to
‘refractoriness’ is unclear.
AED penetration across the blood–brain barrier
Over-expression of the drug transporter P-
glycoprotein (P-gp), encoded by the multidrug
resistance (MDR) gene, has been detected in brain
tissues resected from patients undergoing epilepsy
surgery40. P-gp ‘pumps’ drugs out of cells back
into the blood stream and is expressed in many
blood–tissue barriers. It is situated on the capillary
endothelial cells where it contributes to the integrity
of the blood–brain barrier41. Over-expression of P-
gp by malignant cells is believed to account for their
resistance to anticancer agents42. Similarly, localized
over-expression of P-gp (or other similar families of
transporter) around the seizure focus might inhibit the
penetration of AEDs to the intended site of action,
leading to ‘multidrug resistant’ epilepsy. Recent work
suggests that some AEDs are substrates for P-gp43.
More studies are required to confirm this.
REFRACTORY EPILEPSY AS A
PROGRESSIVE CONDITION
Experimental evidence
There is a substantial body of experimental evidence
to support the concept that refractory epilepsy may
be self-perpetuating. The most thoroughly studied
substrate is that arising from the mesial temporal
lobe44. Recurrent seizures, particularly those involv-
ing the limbic structures, are recognized to cause
enduring disturbances in neuronal function indepen-
dent of underlying pathology24, 26, 45. Characteristic
patterns of neuronal loss and mossy fibre sprouting
associated with human temporal lobe epilepsy can
be produced by prolonged experimental seizures46–49.
Synaptic reorganization in the mossy fibre axons
of hippocampal dentate granule cells into the inner
molecular layer of the dentate gyrus50 can form
functional recurrent excitatory synapses which, in
the presence of reduced inhibition, could promote
seizures51. Whether a brief seizure or even a cluster of
events is sufficient to destroy neurons is less certain,
but the degree of neuronal loss in susceptible regions
of the hippocampus has been shown to correlate
with the number of kindled-seizures52. Even a single
kindled seizure can induce apoptotic neuronal death in
the dentate gyrus53.
Long-lasting changes in excitatory and inhibitory
neurotransmitter receptors and ion channels have
been documented in these animal models of human
epilepsy27, 54. Seizures are also recognized to trigger
a cascade of gene expression including the immediate
early genes such as c-fos55, followed by neurotrophic
factors51, and a variety of late genes encoding a range
of peptides, receptors and cytoskeletal proteins56.
The functional consequences of such neuronal
plasticity remain to be fully elucidated, but these
alterations may lead to a deleterious combination
of disinhibition and hyperexcitability48, 57. Some of
these changes may also account for the phenomenon
of secondary epileptogenesis, which is well-described
in animal models of focal epilepsy. In this scenario,
a primary epileptogenic lesion is able to induce
epileptiform behaviour in an initially normal cell
population via recurrent discharges to create a ‘mirror
focus’ which, in time, becomes an independent source
of epileptic activity58.
Clinical evidence
Are there data to support such self-perpetuation in
human epilepsy? Recent advances in neuroimaging
have allowed in vivo documentation of hippocampal
neuronal loss following prolonged febrile seizures59
and progressive hippocampal atrophy in chronic
refractory temporal lobe epilepsy by serial magnetic
resonance imaging60. Other recent neuroimaging
studies have reported a correlation of increasing
duration of epilepsy and/or numbers of seizures with
more severe neuronal loss and dysfunction in temporal
lobe epilepsy61–63. A long history of seizures prior to
epilepsy surgery is associated with a higher risk of
relapse, supporting the notion of secondary epilepto-
genesis in unresected tissue as a result of recurrent
seizures64. Other surgical studies have reported more
severe cognitive impairment in patients with longer
duration of temporal lobe epilepsy65. Significantly,
such associations have persisted even in patients who
became seizure-free after temporal lobectomy.
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Whether such progression can be observed in
other epilepsy syndromes has been less well studied.
Population-based epidemiological studies have tradi-
tionally failed to demonstrate the self-perpetuating
effect of repeated seizures, particularly in chil-
dren16, 66. Randomized trials suggest that while
AEDs may prevent the immediate occurrence of
seizures associated with febrile illness in children67
or head injury68, the long-term risk of epilepsy
is unaffected. However, these ‘acute symptomatic’
seizures are clearly provoked and would not fulfil
the diagnostic criteria for epilepsy. Electroclinical
studies in patients with tumour-associated epilepsy
support the operation of secondary epileptogene-
sis58, 69. In our recent long-term outcome study of
470 adolescents and adults with newly diagnosed
epilepsy, 47% became seizure-free on the first AED,
13% on a second monotherapy, but only 1% on
the third drug5. The probability of attaining seizure-
freedom declined rapidly and progressively with
successive AED regimens after the first two treatment
manipulations70.
Lastly, outcome studies often focus purely on
seizure control without consideration of the cognitive
and psychosocial aspects of epilepsy. There is evi-
dence to suggest that neuropsychological dysfunction
may not be reversible when the seizure disorder
comes under control64. Surgical outcome studies
indicate that even when the procedure is successful
in eliminating seizures, patients with a long history
of epilepsy often do not gain employment, marry,
or have children, but rather remain dependent on
family and the welfare system71. Such irreversibility
may also explain why patients with childhood-onset
epilepsy suffer social and educational disadvantages
in adulthood well after entering remission13.
REFRACTORY EPILEPSY AS A
PREVENTABLE CONDITION
Can these deleterious neuronal and psychosocial
changes that characterize refractory epilepsy be
prevented by therapeutic intervention? Although
epileptogenesis is a potential target72, 73 and some
AEDs have demonstrated ability to retard the epilep-
togenic process in animal models74, the underlying
neuropathology and the syndromic classification are
at present considered to be constitutively determined.
However, other changes described above may have
developed with time as a result of uncontrolled
seizures. It is tempting to hypothesize that by
interrupting this self-perpetuating process early, the
progression of seizure-related neurobiological, cogni-
tive and psychosocial dysfunction might be halted or
even reversed.
Early identification of refractory epilepsy
This hypothesis contains two important assumptions.
First, it is possible to identify patients at risk of
developing refractory epilepsy early in the disease
process so that effective therapeutic interventions
can be applied. Observational studies have tradi-
tionally highlighted the poor prognostic value of
factors such as an underlying structural abnormality,
high number/frequency of seizures, and abnormal
electroencephalographic findings6. Recently, we have
demonstrated that response to the first AED is
a powerful prognostic indicator. This factor was
particularly predictive among patients in whom
treatment with the first drug was ineffective; only
11% of such patients subsequently became seizure-
free, compared with 41% of the patients who had
intolerable side effects and 55% of those with an
idiosyncratic reaction to the first drug5. Therefore,
in many patients, refractory epilepsy declares itself
early.
Effective therapeutic interventions
Secondly and equally important, effective therapeutic
interventions must exist for this group of patients. The
management of epilepsy is undergoing a revolution.
Advances in neuroimaging have improved the iden-
tification of suitable candidates for epilepsy surgery,
which can render up to 90% of selected patient groups
seizure-free. The most well-defined are those with
HS75. The timing of surgery remains controversial.
Since secondary epileptogenesis at distant sites may
develop with uncontrolled seizures64, early surgery
to avoid deterioration in seizure control and con-
trollability has been advocated. To test this notion,
a randomized controlled trial has been designed
to compare early and delayed surgery in patients
with mesial temporal lobe epilepsy who have failed
two AEDs71.
Parallel to the advances in surgery, nine new
AEDs have been licensed over the past decade. This
expansion of the pharmacological armamentarium has
rekindled interest in searching for ‘synergistic’ AED
combinations76. The argument against combination
therapy traditionally has been its propensity to
produce greater toxicity without substantial improve-
ment in outcome77. However, some of the newer
agents may be better tolerated than their older
counterparts78, potentially enhancing their overall
effectiveness79. Their mechanistic diversity holds out
the possibility of ‘rational’ polytherapy. Although
data directly evaluating the effectiveness of AED
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combinations are scarce, ‘synergistic’ effects of
certain combinations have been explored in laboratory
and clinical studies, particularly those involving the
concomitant use of a sodium channel blocking AED
with one that enhances GABA-ergic inhibition or
has multiple mechanisms of action80. A notable
example is the combination of valproic acid and
lamotrigine75, 81. Combining drugs with different
mechanisms of action to improve efficacy is common
practice in the treatment of other neurological (e.g.
Parkinson’s disease) and non-neurological conditions
(e.g. heart failure). Well-designed studies are re-
quired to examine more fully whether this approach
can be adopted universally in the management of
epilepsy.
A WORKING HYPOTHESIS
Based on these considerations, we wish to propose a
strategic plan for managing epilepsy from the outset.
Such a rational approach is particularly important for
‘high risk’ patients, including those with a known or
probable structural cerebral abnormality (especially
certain pathologies such as HS and CD), or other poor
prognostic clinical factors.
The aim of treatment in all patients should be
the maintenance of a normal lifestyle by complete
seizure control with no side-effects, given that the
majority will respond to monotherapy and require
lifelong treatment. When choosing the first AED, an
accurate classification of the seizure(s) and epilepsy
syndrome is of paramount importance82. In many
situations, more than one AED may be efficacious.
Since significant differences in efficacy between the
AEDs licensed for monotherapy use have not been
demonstrated for the common seizure types in ran-
domized clinical trials83–94, the choice of medication
should take into consideration other factors such as
the individual characteristics of the patients (age,
gender and pregnancy plan, body habitus, concomitant
disease and medications, etc) and the drugs (range
of efficacy, tolerability, side effect and interaction
profile). In this regard, efficacy and tolerability should
both be considered when assessing the effectiveness
of an AED.
If the first AED is not tolerated or the patient
develops an idiosyncratic reaction, obviously the drug
should be substituted. But if seizure control remains
suboptimal despite the patient being able to tolerate
a substantial dose of the first AED, as explored
previously, it is less clear whether the drug should be
substituted or another drug should be added to seek a
‘synergistic’ effect70. A randomized trial comparing
substitution and combination therapy after failure of
the first AED is underway in Glasgow. At present, the
decision to substitute or combine should, among other
factors, depends on the extent of the response to the
first AED and the presence or absence of side-effects.
Our outcome data5 support the assertion that
failure of two first-line AEDs as monotherapy due
to lack of efficacy should prompt consideration of
epilepsy surgery in a patient with a resectable brain
abnormality, in particular HS71. For the majority of
patients not suitable for ‘curative’ surgery, two (or at
most three) AEDs should be combined in a ‘rational’
fashion95. This should involve consideration of
mechanism of action, as well as the range of efficacy,
propensity for adverse interactions (pharmacokinetic
and pharmacodynamic), and side-effect profile.
Conceptualization of refractory epilepsy as a dis-
tinct condition characterized by progressive neuronal,
cognitive and psychosocial deterioration would allow
a better appreciation of its multifaceted dimensions.
We propose that failure of two first line AEDs due
to lack of efficacy or poor tolerability should prompt
consideration of epilepsy surgery or combination AED
therapy with the aim of achieving ‘synergy’. This
strategy has the potential to improve outcome by
preventing the insidious progression to intractable
‘refractoriness’ and a downward spiralling quality of
life.
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